Mechanical circulatory support is now a reliable and accessible therapeutic option for patients with advanced cardiac failure or cardiogenic shock.
Answers are grounded in this paper and cite their sources.
Supports expanded MCS consideration in advanced HF; leaves open need for prospective trials on durability and selection.
Mechanical circulatory support is becoming an alternative therapeutic option for patients in cardiogenic shock or advanced cardiac failure who cannot be improved by maximal medical therapy. More than 30 years of engineering development and clinical research have led to a level of efficacy and reliability of ventricular assist devices, which allows promotion of this approach for the most difficult patients. Uses include a gaining-time strategy as a bridge to cardiac transplantation or recovery of native cardiac function, as well as permanent support with the device. The large variety of devices permits every cardiac surgical unit, even those not used to cardiac transplantation, to propose this option to the patient. Recent experience with small silent implantable pumps suggests that the pioneering period of mechanical circulatory support is probably over, and the time has come for precise prospective trials to optimize both patient selection and the timing for utilization. In countries where cardiac transplantation has not developed, there is now an easily accessible technique for management of patients with cardiac failure.
No takes yet. Share an insight, caveat, or question.
D Loisance (2008) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: